NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 216 filers reported holding NEKTAR THERAPEUTICS in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $0 | -100.0% | 34 | -99.3% | 0.00% | -100.0% |
| Q2 2022 | $19,000 | – | 4,946 | +10891.1% | 0.00% | – |
| Q1 2022 | $0 | -100.0% | 45 | -40.0% | 0.00% | – |
| Q4 2021 | $1,000 | -94.1% | 75 | -91.9% | 0.00% | -100.0% |
| Q3 2021 | $17,000 | -19.0% | 926 | -25.7% | 0.00% | 0.0% |
| Q2 2021 | $21,000 | +16.7% | 1,247 | +34.8% | 0.00% | 0.0% |
| Q1 2021 | $18,000 | -50.0% | 925 | -55.5% | 0.00% | 0.0% |
| Q4 2020 | $36,000 | +200.0% | 2,080 | +186.5% | 0.00% | +33.3% |
| Q3 2020 | $12,000 | +71.4% | 726 | +132.7% | 0.00% | +50.0% |
| Q2 2020 | $7,000 | – | 312 | +1460.0% | 0.00% | – |
| Q1 2020 | $0 | – | 20 | +150.0% | 0.00% | – |
| Q2 2019 | $0 | – | 8 | +14.3% | 0.00% | – |
| Q4 2018 | $0 | – | 7 | +40.0% | 0.00% | – |
| Q2 2018 | $0 | -100.0% | 5 | 0.0% | 0.00% | -100.0% |
| Q1 2018 | $1,000 | – | 5 | 0.0% | 0.00% | – |
| Q4 2017 | $0 | – | 5 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |